Kunshi Biotechnology is a biotechnology company that recently attracted new institutional interest. According to DoNews, the firm has closed a RMB 50 million Series A financing round. The brief announcement did not disclose the company’s specific products, research focus, target markets, or customer traction. It also offered no data on revenue, users, or other operating metrics. Financially, the Series A infusion represents the company’s latest external capital and positions it for its next phase of development. No information was provided on how the funds will be allocated or on any previous funding history.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2025